Articles tagged with Biomarkers
Scientists have identified molecular differences between disease-indicating proteins and those that exist naturally, enabling the development of reliable diagnostic tests. This breakthrough could lead to earlier diagnosis and treatment of fatal diseases, such as cancer.
Researchers at the University of Cambridge identified a biomarker for autism in siblings of individuals with autism, showing reduced brain activity to emotional facial expressions. This finding provides an opportunity to investigate genes linked to autism and sheds light on why some family members are more affected than others.
A new study found that a protein called soluble amyloid precursor protein beta (sAPPβ) may be a more accurate predictor of Alzheimer's disease than existing biomarkers. The researchers discovered that sAPPβ levels were significantly higher in participants who developed the disease, with an average of 1,200 nanograms per milliliter.
Researchers from Boston University School of Medicine found that measuring carbohydrate-deficient transferrin (CDT) biomarker was a poor method for detecting unhealthy drinking among HIV-infected adults. The study suggests that CDT is not sufficiently sensitive for use in screening for unhealthy alcohol use in people with HIV infection.
Researchers at Fred Hutchinson Cancer Center demonstrate a staged, targeted pipeline approach using mass spectrometry to prioritize and validate protein biomarkers in mice. This method enables the testing of a larger number of biomarker candidates than conventional technologies, improving the efficiency of biomarker evaluation. The stu...
A study found that a low-saturated fat and low-glycemic index diet decreased certain biomarkers of Alzheimer's disease in healthy adults, while also improving memory performance. However, the diet had the opposite effect on individuals with mild cognitive impairment, potentially due to its short duration.
A study published in JAMA found that highly cited studies on biomarkers often reported larger effect size estimates than subsequent meta-analyses, suggesting potential for false-positive results. This can lead to wasted resources and inaccurate risk appraisal if not addressed by conducting more evidence.
Researchers analyzed 35 highly-cited studies and found that fewer than half of biomarkers had statistically significant associations with disease risk in larger follow-up studies. Only one in five original studies increased a patient's relative risk for a condition by more than 1.37.
A study found that elderly patients with heart failure symptoms who have high levels of biomarkers copeptin and NT-proBNP in their blood have an increased risk of all-cause death. The combination of these biomarkers provides greater prognostic information, suggesting potential therapeutic targets for treatment.
Researchers at Thomas Jefferson University discovered a biomarker Stat5 in breast cancer that predicts patient response to anti-estrogen therapy tamoxifen. Women with active Stat5 have an increased likelihood of responding to the treatment, while those without it are at a higher risk of dying from breast cancer.
Researchers use a genetically re-engineered herpes virus that selectively infects cancer cells, prompting them to secrete a biomarker that can be detected. The technology has the potential to improve cancer diagnosis and monitoring, especially in less developed parts of the world.
GEN reports on innovative approaches to detect cancer at an early stage, with potential benefits of reduced invasive biopsies and imaging studies. Researchers are validating biomarkers like CA125 and matrix metalloproteases in urine for ovarian cancer detection.
The National Institute on Aging/Alzheimer's Association Diagnostic Guidelines for Alzheimer's Disease outline new approaches for clinicians and researchers. The guidelines cover the full spectrum of the disease, including preclinical stages, mild cognitive impairment, and dementia due to Alzheimer's pathology.
Researchers at Goethe University and Harvard Medical School develop screening method for active ingredients to treat Batten disease, a devastating disorder affecting vision and motor abilities. The breakthrough uses innovative microscopy technology and identifies biomarkers for potential drug intervention.
A study of 26,643 U.S. adults found that combining creatinine, cystatin C, and urine albumin-to-creatinine ratio improved prediction of end-stage renal disease and all-cause death. The researchers identified a 3-fold risk of death and 4-fold risk of end-stage renal disease associated with the combined markers.
Researchers validated three salivary mRNA biomarkers (B2M, GIP2, MNDA) and three protein biomarkers (B2M, SSA, SSB) for detecting Sjogren's syndrome in the US population, expanding clinical utility of existing biomarkers.
Researchers identified four novel biomarkers that can discriminate between healthy controls, asthmatics, and individuals with COPD. These anti-inflammatory proteins may help diagnose respiratory diseases earlier, allowing for more effective treatment.
Case Western Reserve University School of Medicine researchers have identified a new biomarker for sporadic Creutzfeldt-Jakob disease (sCJD), a degenerative brain disease with no cure. The biomarker, transferrin, shows promise in early diagnosis and potential therapy development.
Researchers have identified a new biomarker for sporadic Creutzfeldt-Jakob disease, which can accurately diagnose the condition in patients while they are still alive. The biomarker, transferrin, is significantly decreased in the cerebrospinal fluid of patients with sCJD before the end stage of the disease.
A nearly $2 million NIH grant will help Nationwide Children's Hospital investigate biomarkers linked to hemangioma development and outcome. The study aims to understand the role of oxidant production in hemangioma formation.
Researchers at The Wistar Institute and University of Pennsylvania School of Medicine have discovered protein markers that could predict ectopic pregnancies. A panel of biomarkers, weighing individual proteins' relative importance, may create a more sensitive and reliable test for detecting ectopic pregnancies.
A newly discovered biomarker could help doctors diagnose meniscal tears with high accuracy, avoiding unnecessary surgery and medical scans. The biomarker, a fibronectin-aggrecan complex, was found in the knee fluid of patients with painful meniscal tears but not in asymptomatic individuals.
Researchers have developed a novel technology to diagnose Alzheimer's disease from blood samples before symptoms appear, identifying two potential biomarkers with 90% accuracy. This breakthrough could lead to earlier intervention and improved outcomes for patients.
Researchers create microsponges that capture biomarkers, enabling rapid disease diagnosis with high accuracy. The technology has the potential to replace traditional diagnostic methods at a lower cost.
Researchers at the University of Manchester have discovered a blood-clotting agent that can diagnose and monitor treatment for childhood genetic diseases. The biomarker, heparan cofactor II/thrombin (HCII/T) complex, accurately distinguishes between untreated patients with various MPS conditions.
A team of researchers has identified a potential biomarker for predicting future metastasis in patients with the most common form of liver cancer. Quantification of the mRNA template for a truncated version of the protein carboxypeptidase E (CPE) was found to predict intrahepatic metastasis with high sensitivity and specificity.
A new study found that traditional dietary surveys, relying on self-reported data, are inconsistent and can be influenced by memory impairment and digestive issues. Using nutrient biomarkers through blood tests, researchers aim to improve the accuracy of nutritional assessments and develop more effective therapies for cognitive health.
A study found that lower levels of beta-amyloid protein fragments, combined with less education, are associated with a faster rate of cognitive decline over nine years. Cognitive reserve measures modified the association, with those having higher reserves showing less decline.
The top biotech acquisitions in 2010 that exceeded $1 billion included a $41 billion purchase of Alcon by Novartis, followed by a $18.5 billion bid for Genzyme from sanofi-aventis. Merck's $5.2 billion acquisition of Millipore and Teva's €3.625 billion purchase of ratiopharm also made the list.
Researchers identify potential antibody biomarkers for Alzheimer's, Parkinson's and multiple sclerosis using synthetic compounds. Synthetic peptoids capture immunoglobulin antibodies from blood samples with high accuracy.
Researchers have developed a new type of sensor that can rapidly detect biomarkers in real time, enabling an inexpensive and quick way to collect diagnostic information about patients. The technology has the potential to diagnose cancer and other diseases by detecting specific compounds in a person's breath.
Researchers found that patients who developed immune reconstitution inflammatory syndrome (IRIS) after starting HIV therapy had specific biomarker patterns in their blood. The study suggests that prediction of IRIS or death may be possible with measurement of pre-antiretroviral therapy serum biomarkers.
Researchers at Arizona State University have identified a broad panel of 28 early predictors, or biomarkers, that may aid in the early diagnosis of breast cancer. The biomarkers were specific to breast cancer patients and not found in healthy women or those with benign breast disease.
A new study found that cardiac troponin T levels detected with a highly sensitive assay are associated with structural heart disease, cardiovascular mortality, and increased all-cause death in the general population. The prevalence of detectable cTnT varied by sex, race, age, and comorbidities.
Researchers at SomaLogic describe a breakthrough technology that detects biomarkers for lung cancer in its early stages, revealing the presence of a panel of 12 proteins. The SOMAmer technology enables accurate detection and measurement of proteins in just a few drops of blood.
A new study has identified promising biomarkers for Huntington's disease that could be used to track disease progression and test potential disease-modifying treatments. Biomarkers were found in brain imaging techniques, including whole-brain and striatal atrophy, which increased at a higher rate in individuals with the disease.
A study funded by the Motor Neurone Disease Association has identified a common signature of nerve damage in MND patients' brains, using advanced MRI techniques. This finding holds promise for a biomarker that could improve diagnosis speed and accuracy, as well as assess future treatments.
Researchers identified placental growth factor as a promising diagnostic biomarker for ectopic pregnancies. The study found that PIGF levels were reduced in samples from tubal ectopic pregnancies compared to intrauterine pregnancies.
Researchers have discovered haptoglobin as a reliable serum biomarker for predicting the onset of virus-induced type 1 diabetes in rats. The findings suggest that sustained elevations of serum haptoglobin are predictive of ensuing diabetes, with early detection potentially allowing for timely intervention.
A study found that measuring three biomarkers in a single blood sample can improve physicians' ability to identify patients at high risk of developing CKD. The biomarkers included homocysteine, aldosterone, and B-type natriuretic peptide.
A new definition of Alzheimer's disease has been proposed to diagnose the condition earlier and select patients for trials of disease-modifying treatments. The revised definition includes biomarkers as a key diagnostic feature, enabling diagnosis at an earlier stage, and allows for more precise selection of patients for clinical trials.
Erlotinib has been shown to improve progression-free survival in patients with advanced lung cancer carrying EGFR activating mutations. The OPTIMAL trial found that erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination. Safety analyses also showed lower rates of adverse events with erlotinib.
UT Southwestern researchers have found a set of proteins in blood serum that shows promise as a sensitive and accurate way to diagnose Alzheimer's disease. The analysis proved 94 percent accurate in detecting suspected Alzheimer's and 84 percent accurate in ruling it out in people without the disease.
The Penn Medicine Parkinson's Disease and Movement Disorders Center is one of 18 official study sites for the PPMI, a $40 million, 5-year observational clinical study that aims to identify biomarkers of Parkinson's disease progression. The study will use advanced imaging, biologics sampling, and behavioral assessments to provide valuab...
Researchers have identified a single biomarker that may predict resistance to tivozanib in patients with kidney and breast cancer. The biomarker reflects the presence of white blood cells inside tumors and is associated with clinical activity.
Researchers have developed a biomarker panel that distinguishes prostate cancer from benign prostate disease and healthy tissue with high accuracy. The panel uses autoantibodies to identify proteins on the surface of cancer cells, enabling early diagnosis and potentially increasing cure rates.
Dr. Jerrold J. Ellner leads an international research team to identify biological markers for tuberculosis (TB) and develop novel treatments and vaccines. The five-year grant aims to prevent TB, which kills nearly two million people annually.
Research led by Nancy F. Butte and funded by the US Department of Agriculture identifies new genetic biomarkers that may predict type 2 diabetes in children. The study fine-tunes a region on chromosome 13 associated with fasting blood sugar levels, shedding light on predisposition to the disease.
A study analyzing protein biomarkers in blood serum identified individuals with Alzheimer's disease with high accuracy. The findings suggest an inflammatory subtype of the disease and hold potential for targeted therapeutics.
Scientists at NPL have developed a new strategy for quicker and more precise detection of biomarkers, proteins indicating disease. This approach uses a probe to 'fish' for likely proteins in crowded blood samples, potentially leading to earlier diagnosis and treatment of Alzheimer's and cancer.
Despite advancements in cancer biomarker research, many initial breakthroughs fail to translate to clinical success due to issues with study design and interpretation. Seven biomarkers initially hailed as promising have been reevaluated, highlighting problems with pre-analytical, analytical, and post-analytical study design.
Researchers will study immune cells to identify biomarkers associated with TB infection and disease reactivation. The joint laboratory aims to develop early diagnosis and effective treatment for the highly contagious disease, affecting millions worldwide.
Researchers at CWRU School of Dental Medicine discovered a biomarker called human beta defensin-3 (hBD-3), which is associated with the early stages of oral cancer and can serve as an early warning system. hBD-3 attracts molecules that help cancerous tumors grow and spread.
Researchers at The Chinese University of Hong Kong have identified biomarkers in preterm infants' blood that can detect late-onset septicemia and necrotizing enterocolitis. These findings may help diagnose preterm infants requiring urgent treatment, reducing the risk of life-threatening conditions.
Researchers at TGen and VARI discovered a biomarker, miR-92a-2*, linked to survival in SCLC patients. Higher tumor levels of this microRNA are associated with chemoresistance and decreased survival.
A recent study suggests that N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) is not a reliable biomarker for cardiac dysfunction in dialysis patients. Instead, high NT-pro-BNP levels are more closely associated with fluid overload and require adjustment of dry weight to prevent complications.
New drugs, vaccines, biomarkers, and diagnostics could reduce TB incidence by 94% by 2050. Biomarker development is crucial for predicting treatment outcomes, while diagnostics advancements aim to improve case detection.
Scientists identified a tiny gene mutation that alters liver enzyme production, affecting drug processing and dosing. This mutation may serve as a biomarker to predict toxicity thresholds in cancer patients and tailor medication doses.
The Biodesign Institute project seeks to discover and validate molecular signs to predict who will develop diabetes before symptoms appear. By analyzing blood samples from over 700 patients, researchers hope to identify new biomarkers that can identify those at risk for developing diabetes and heart disease.
A team of researchers from McGill/MUHC has developed a novel screening tool to diagnose Chagas disease, a parasitic disease affecting over 10 million people in the Americas. The new approach uses mass spectrometry technology to identify specific biological markers left by the parasite, enabling rapid and reliable diagnosis.